secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0000950170-23-007002
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma FY2022 cash $69.3M; Phase 3 EFZO-FIT enrolling globally; $52M Feb offering extends runway to 2026
--------------------------------------------------------------------------------

- Cash & investments $69.3M at Dec 31, 2022; Feb 2023 offering raised ~$52M gross plus $10M milestone from Kyorin; runway into 2026.
- R&D expense $42.8M, G&A $14.0M for full year 2022; pre-revenue biotech with no product sales.
- Phase 3 EFZO-FIT (sarcoidosis) enrolling in U.S., Europe, Japan; Kyorin dosed first patient in Japan triggering $10M milestone.
- FDA cleared IND for Phase 2 proof-of-concept SSc-ILD study; EU orphan designation for efzofitimod in sarcoidosis.
- LTBP1 identified as target of DARS domain; European patent allowance for efzofitimod + pirfenidone combo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/0000950170-23-007002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023007002/life-20230309.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer